SGLT2 inhibitor benefits cardiac patients without diabetes: study

Research suggests gliflozins may do more than lower glucose

Patients with heart failure who don’t have diabetes benefit from being prescribed dapagliflozin as much as those with the disease, suggests a ground-breaking study.


Results from the DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) trial add to a growing body of evidence that SGLT2 inhibitors can be used outside the glucose-lowering setting.

The Scottish-led research randomly assigned 4700 patients (mean age 66) with heart failure and an ejection fraction below 40% to either 10mg once-daily dapagliflozin or placebo, in addition